https://www.selleckchem.com/pr....oducts/brm-brg1-atp-
Adverse effects such as hypoglycaemia, gastrointestinal upset and pancreatitis were infrequent. On current evidence, the small benefit in glycaemic control that may be realized by using combination incretin therapy is unlikely to be offset by the potential increased risk of pancreatitis or additional cost. #link# Additional long-term prospectively designed studies are needed to better understand the efficacy and safety of combination incretin therapy. On current evidence, the small benefit in glycaemic control that may
Mi piace
Commento
Condividi
